BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19519437)

  • 1. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.
    Wolff D; Steiner B; Hildebrandt G; Edinger M; Holler E
    Curr Pharm Des; 2009; 15(17):1974-97. PubMed ID: 19519437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in the prophylaxis and treatment of graft versus host disease.
    Simpson D
    Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thinking out of the box--new approaches to controlling GVHD.
    Baron F; Humblet-Baron S; Ehx G; Servais S; Hannon M; Belle L; Lechanteur C; Briquet A; Giet O; Baudoux E; Willems E; Beguin Y
    Curr Hematol Malig Rep; 2014 Mar; 9(1):73-84. PubMed ID: 24390548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
    Wolff D; Gerbitz A; Ayuk F; Kiani A; Hildebrandt GC; Vogelsang GB; Elad S; Lawitschka A; Socie G; Pavletic SZ; Holler E; Greinix H
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1611-28. PubMed ID: 20601036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
    Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
    Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for graft-versus-host disease.
    Jacobsohn DA
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):323-38. PubMed ID: 14661992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions.
    Martinez-Cibrian N; Zeiser R; Perez-Simon JA
    Blood Rev; 2021 Jul; 48():100792. PubMed ID: 33386151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
    Xhaard A; Hermet E; Bay JO; Peffault de Latour R
    Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study.
    Sakellari I; Gavriilaki E; Batsis I; Mallouri D; Panteliadou AK; Lazaridou A; Vardi A; Constantinou V; Yannaki E; Papalexandri A; Kaloyannidis P; Smias C; Anagnostopoulos A
    J Clin Apher; 2018 Dec; 33(6):654-660. PubMed ID: 30394564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
    Kim SS
    Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Servais S; Beguin Y; Delens L; Ehx G; Fransolet G; Hannon M; Willems E; Humblet-Baron S; Belle L; Baron F
    Expert Opin Investig Drugs; 2016 Aug; 25(8):957-72. PubMed ID: 27110922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of graft-versus-host disease.
    Arai S; Vogelsang GB
    Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease.
    Michael M; Shimoni A; Nagler A
    Isr Med Assoc J; 2013 Jan; 15(1):44-50. PubMed ID: 23484241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.
    Potter V; Moore J
    Rev Recent Clin Trials; 2008 May; 3(2):130-8. PubMed ID: 18474024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute graft versus host disease (GvHD).
    Bacigalupo A; Palandri F
    Hematol J; 2004; 5(3):189-96. PubMed ID: 15167903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.